RespireRx Pharmaceuticals (OTC:RSPI) Ltd and its ResolutionRx subsidiary announced that it has entered into a Master Services Agreement (MSA) with Australia’s Ab Initio Pharma Pty Ltd (Ab Initio), under which Ab Initio will manufacture, formulate, test and supply ResolutionRx with therapeutic drugs based on lipid nanoparticle technology licensed from RespireRx.
The biopharma company said the initial services relate to ResolutionRx’s repurposing of dronabinol and its development program for obstructive sleep apnea pursuant to which Ab Initio will, among other things, manufacture and test its new dronabinol lipid nanoparticle formulation for pharmacokinetic, pharmacodynamic, and pivotal clinical trials, as well as ultimately for commercialization.
"With its formulation expertise and GMP manufacturing facilities, Ab Initio will complete our original laboratory experiments to determine a final, optimum dronabinol formulation, scale up and manufacture the chosen formulation for clinical use," RespireRx Pharmaceuticals (OTC:RSPI) CEO Arnold Lippa said in a statement.
"The lipid nanoparticle technology not only represents a major step forward in the development of dronabinol, but the potential for more widespread use for insoluble or poorly soluble drugs," he added.
The initial term of the MSA is two years and automatically renews for one-year periods unless ResolutionRx provides written notice to Ab Initio of its intent not to renew at least 90 days prior to the end of the initial term or any renewal term.
RespireRx Pharmaceuticals and its subsidiaries and business units (RespireRx Group) are discovering and developing medicines for the treatment of psychiatric and neurological disorders, including obstructive sleep apnea (OSA), attention deficit hyperactivity disorder (ADHD), epilepsy, pain, recovery from spinal cord injury (SCI), and certain neurological orphan diseases.
Contact Sean at sean@proactiveinvestors.com